IP Library › Granted Patent US 7,960,100
Granted Patent B1
US 7,960,100 · App. 12/077,323 · Granted Jun 14, 2011

Colon cancer targets and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,960,100
App. No.
12/077,323
Granted
Jun 14, 2011
Kind
B1
Abstract

The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.

Claims (3)

1. A method of diagnosing colon cancer in an individual, the method comprising detecting an elevated level of solute carrier family 5, member 1 (SLC5A1) protein in a colon sample from the individual relative to a control SLC5A1 protein level of a non-cancerous colon tissue sample, wherein the elevated level of SLC5A1 protein indicates that said individual has colon cancer, and wherein the SLC5A1 protein comprises the amino acid sequence of SEQ ID NO:651.

2. The method of claim 1 , wherein the elevated level of the SLC5A1 protein is detected by contacting the sample from the individual with an isolated antibody that selectively binds to the SLC5A1 protein and detecting binding of the antibody to the SLC5A1 protein.

3. The method of claim 2 , wherein the antibody is coupled to a detectable substance.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2008
From: APPLERA CORPORATION
To: CELERA CORPORATION
Reel/Frame 021561/0124 →